CEO Ameet Mallik stated the company "continue[s] to focus on execution and delivering on our commercial strategy, maintaining ZYNLONTA as a differentiated treatment option for third-line plus DLBCL ...

CEO Ameet Mallik reported that "the first quarter of 2025 represented a solid period of continued performance for our company," highlighting total first quarter revenues of $23 million, with net ...